These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 31170937)

  • 1. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.
    Liu C; Chu X; Sun P; Feng X; Huang W; Liu H; Ma Y
    Hum Vaccin Immunother; 2018 Apr; 14(4):931-940. PubMed ID: 29271696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
    Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
    J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
    Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
    Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity.
    Song YC; Cheng HY; Leng CH; Chiang SK; Lin CW; Chong P; Huang MH; Liu SJ
    J Control Release; 2014 Jan; 173():158-65. PubMed ID: 24177312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
    Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
    Front Immunol; 2021; 12():803090. PubMed ID: 35003132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors.
    Domingos-Pereira S; Galliverti G; Hanahan D; Nardelli-Haefliger D
    J Immunother Cancer; 2019 May; 7(1):122. PubMed ID: 31060612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
    J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
    Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
    Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
    Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC
    J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
    Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
    J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.